Overview

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the pharmacokinetics (PK) of single-dose ORF tablets in pediatric patients aged 6 to 16 years, inclusive.

Phase:

Phase 1

Details

Lead Sponsor:

Purdue Pharma LP

Treatments:

Oxycodone